Anzeige
Mehr »
Freitag, 10.04.2026 - Börsentäglich über 12.000 News
Die Bohrer rollen - der Durchbruch-Moment ist da
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W1ZU | ISIN: US00770C1018 | Ticker-Symbol: OXQ1
Tradegate
09.04.26 | 20:03
1,850 Euro
+1,09 % +0,020
1-Jahres-Chart
ARQ INC Chart 1 Jahr
5-Tage-Chart
ARQ INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,7601,83013:13
1,7601,83012:40

Aktuelle News zur ARQ Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.04.Arq, Inc. - 8-K, Current Report1
24.03.Arq, Inc.: Arq to Participate in Water Tower Research Fireside Chat Series on March 25, 20263
11.03.Canaccord cuts Arq stock price target on GAC production pause4
10.03.Clear Street cuts Arq stock price target on GAC production pause2
10.03.Arq outlines 2026 revenue and EBITDA guidance as GAC project paused for optimization3
ARQ Aktie jetzt für 0€ handeln
10.03.Arq shares plunge 46% after weak earnings, disappointing 2026 outlook8
10.03.Morning Market Movers: MiNK Therapeutics, Garden Stage, Arq, Inc., SciSparc See Big Swings519BEIJING (dpa-AFX) - At 8:05 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening...
► Artikel lesen
10.03.Arq reports mixed Q4 results; provides inaugural financial guidance for FY264
10.03.Arq, Inc. Q4 Loss Increases4
09.03.Arq, Inc.: Arq Reports Fourth Quarter and Full Year 2025 Results925Generated record revenue of approximately $120 million for full-year 2025, driven by PAC performance Reported Adjusted EBITDA(1) of $13 million, representing 26% improvement year-over-year Provided...
► Artikel lesen
06.03.Arq Q4 2025 Earnings Preview3
06.03.Insights into Arq's Upcoming Earnings2
03.03.Arq, Inc. - 8-K, Current Report2
03.03.Arcutis enrolls first patient in ARQ-234 atopic dermatitis trial1
03.03.Arcutis Biotherapeutics, Inc.: Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis747Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitisARQ-234 is a potent fusion-protein...
► Artikel lesen
29.01.Arq, Inc. - 8-K, Current Report1
11.12.25Arq, Inc. - 8-K, Current Report-
10.12.25Arq (ARQ): Clear Street Reiterates Buy Rating3
06.11.25Arq Inc. verfehlt Q3-Prognosen: Aktie bricht nach enttäuschenden Zahlen ein3
05.11.25Arq, Inc.: Arq Reports Third Quarter 2025 Results214Generated revenue of $35 million, driven by strong performance of the foundational PAC business Reported Adjusted EBITDA of $5.2 million, achieving sixth consecutive quarter of positive Adjusted EBITDA...
► Artikel lesen
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1